Clinical Trials for Kidney Cancer

A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced, refractory solid tumors and ECOG performance status 0–1 receive intravenous IBI363 every 2 or 3 weeks. IBI363 is an investigational PD-1/IL-2α-biased fusion protein designed to combine PD-1 blockade with IL-2 signaling directed preferentially toward PD-1-positive T cells.

ClinicalTrials.gov ID: NCT06281678

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced or metastatic clear cell RCC that has progressed after PD-1/PD-L1 inhibitor therapy receive ivonescimab, an intravenous bispecific antibody targeting PD-1 and VEGF-A, every three weeks. One cohort has had no prior VEGF- or HIF-2α-directed therapy; the other has progressed on or after VEGF-directed therapy.

ClinicalTrials.gov ID: NCT06940518

EXACT: Randomized Phase II Trial of XL092 in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with measurable advanced or metastatic clear-cell RCC that progressed on or after adjuvant PD-1/PD-L1 therapy, with no other prior systemic therapy, are randomized to zanzalintinib (XL092) alone or with nivolumab. Zanzalintinib is an investigational inhibitor of VEGFR2, MET, and the TAM kinases TYRO3, AXL, and MER; nivolumab inhibits PD-1.

ClinicalTrials.gov ID: NCT06863311

A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: For adults with unresectable locally advanced or metastatic clear cell renal cell carcinoma that has progressed on or after anti-PD-1/PD-L1 therapy, this trial compares oral casdatifan plus cabozantinib with placebo plus cabozantinib. Casdatifan is an investigational HIF-2α inhibitor; prior treatment with a HIF-2α inhibitor or cabozantinib is excluded.

ClinicalTrials.gov ID: NCT07011719

A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated, unresectable locally advanced or metastatic clear-cell RCC across all IMDC risk groups are randomized to fianlimab (investigational anti-LAG-3 antibody) plus cemiplimab (anti-PD-1), with or without ipilimumab (anti-CTLA-4), or standard ipilimumab plus nivolumab (anti-PD-1).

ClinicalTrials.gov ID: NCT07188896

A Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma - SPARCC

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated, unresectable advanced or metastatic clear cell RCC (including sarcomatoid histology) or translocation RCC receive sasanlimab (an investigational anti–PD-1 antibody), palbociclib (a CDK4/6 inhibitor), and axitinib (a VEGF-pathway inhibitor).

ClinicalTrials.gov ID: NCT07123090

A Randomized Phase II Trial of Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Oligo-Metastatic Clear Cell Renal Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with clear cell renal cell carcinoma and 1–5 metastatic lesions amenable to stereotactic body radiotherapy (SBRT) receive SBRT to active sites, then are randomized to cemiplimab (anti–PD-1) alone or with investigational fianlimab (anti–LAG-3) every 3 weeks for up to 1 year.

ClinicalTrials.gov ID: NCT07223541

A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable stage IV clear-cell RCC that recurred during or within 24 months after adjuvant anti-PD-1/L1 therapy, and no other prior systemic RCC therapy, receive oral belzutifan plus zanzalintinib or oral cabozantinib. Belzutifan inhibits HIF-2α; investigational zanzalintinib inhibits VEGFR2, MET, and TAM-family kinases.

ClinicalTrials.gov ID: NCT07227402

A Phase II Study of Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases in Patients Previously Treated With Immune Checkpoint Inhibitors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic predominantly clear cell RCC, at least three bone metastases, and 1–3 prior treatment lines including an immune checkpoint inhibitor receive oral zanzalintinib plus a bone-strengthening agent. Zanzalintinib is an investigational tyrosine kinase inhibitor targeting VEGFR2, MET, and the TAM kinases TYRO3, AXL, and MER.

ClinicalTrials.gov ID: NCT07043608

A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants With Advanced RCC Who Have Progressed on or After Both PD-1/L1 and VEGF-TKI Therapies in Sequence or in Combination (LITESPARK-034)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This study enrolls patients with unresectable stage IV clear-cell RCC that has progressed after both PD-1/PD-L1 and VEGF-TKI therapy, with no more than three prior systemic regimens. Patients receive the HIF-2α inhibitor belzutifan plus either investigational zanzalintinib, a VEGFR2/MET/TAM kinase inhibitor, or placebo.

ClinicalTrials.gov ID: NCT07489495